- Home
- VRNA
VRNA
Verona Pharma plc
as 06-06-2025 4:00pm EST
| Founded: | 2005 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | N/A | IPO Year: | 2017 |
| Target Price: | $78.80 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.79 - $86.59 | Next Earning Date: | 04-29-2025 |
| Revenue: | $118,535,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 890.44% | Revenue Growth (next year): | 77.74% |
Stock Insider Trading Activity of Verona Pharma plc (VRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ZACCARDELLI DAVID | VRNA | President and CEO | May 27 '25 | Sell | $9.39 | 400,000 | $3,734,578.84 | 13,956,568 | |
| Hahn Mark W | VRNA | Chief Financial Officer | May 27 '25 | Sell | $9.39 | 400,000 | $3,733,944.47 | 13,046,560 | |
| Sinha Vikas | VRNA | Director | May 20 '25 | Sell | $9.39 | 160,000 | $1,502,928.00 | 74,440 | |
| Fisher Andrew | VRNA | General Counsel | May 15 '25 | Sell | $8.57 | 80,000 | $685,600.00 | 359,999 | |
| ACKERMANN CHRISTINA | VRNA | Director | May 14 '25 | Sell | $8.44 | 40,000 | $337,600.00 | 41,880 | |
| Rickard Kathleen A. | VRNA | Chief Medical Officer | May 6 '25 | Sell | $8.82 | 114,984 | $1,014,342.85 | 2,546,472 | |
| ZACCARDELLI DAVID | VRNA | President and CEO | May 1 '25 | Sell | $9.00 | 587,008 | $5,311,279.00 | 13,956,568 | |
| Hahn Mark W | VRNA | Chief Financial Officer | May 1 '25 | Sell | $9.00 | 587,008 | $5,311,479.00 | 13,046,560 | |
| Rickard Kathleen A. | VRNA | Chief Medical Officer | May 1 '25 | Sell | $8.95 | 49,200 | $440,349.84 | 2,546,472 | |
| Sinha Vikas | VRNA | Director | Apr 29 '25 | Sell | $8.92 | 180,000 | $1,605,744.00 | 74,440 |
Latest Verona Pharma plc News
VRNA Breaking Stock News: Dive into VRNA Ticker-Specific Updates for Smart Investing
Motley Fool
2 days ago
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today
Insider Monkey
9 days ago
Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”
GlobeNewswire
17 days ago
Verona Pharma Announces June 2025 Investor Conference Participation
Insider Monkey
25 days ago
Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now
Insider Monkey
a month ago
What Makes Verona Pharma plc (VRNA) a Good Investment?
Investor's Business Daily
a month ago
IBD Stock Of The Day Verona Pharma Tests Buy Point After Earnings Breakout
GlobeNewswire
a month ago
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
MT Newswires
a month ago
Verona Pharma Insider Sold Shares Worth $811,433, According to a Recent SEC Filing
Compare VRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRNA Verona Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.